Tebotelimab

• CAT Number: I042117
• CAS Number: 2245725-04-4
• Purity: ≥95%

Tebotelimab (CAT No.: I042117) is a bispecific monoclonal antibody designed to simultaneously block PD-1 (programmed cell death protein 1) and LAG-3 (lymphocyte-activation gene 3), two key immune checkpoint receptors that suppress T-cell activation. By inhibiting both pathways, Tebotelimab enhances antitumor immune responses more effectively than monotherapies. It is under investigation for treating various solid tumors and hematologic malignancies. Tebotelimab represents a next-generation immunotherapy approach, aiming to overcome resistance to single checkpoint inhibitors and improve outcomes in cancer immunotherapy through dual immune checkpoint blockade.

Reference

[1]. Ross LaMotte-Mohs, et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Res (2016) 76 (14_Supplement): 3217.

[2]. Daniel Vt Catenacci, et al.MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr;17(10):1155-1164.
[Content Brief]

[3]. Yiming Wei, et al. LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance. Front Oncol. 2022 Apr 14;12:831407.
[Content Brief]